

Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.

Emmanuelle Comets, Bertrand Diquet, Sylvie Legrain, Marie-Geneviève Huisse, Alban Godon, Corinne Bruhat, Marie-Paule Chauveheid, Sandrine Delpierre, Xavier Duval, Gilles Berrut, et al.

► **To cite this version:**

Emmanuelle Comets, Bertrand Diquet, Sylvie Legrain, Marie-Geneviève Huisse, Alban Godon, et al.. Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.. *Clinical Pharmacology and Therapeutics*, American Society for Clinical Pharmacology and Therapeutics, 2012, 91 (5), pp.777-86. <10.1038/clpt.2011.309>. <inserm-00707899>

HAL Id: inserm-00707899

<http://www.hal.inserm.fr/inserm-00707899>

Submitted on 1 Nov 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians

Authors: Emmanuelle Comets^{1,2}, Bertrand Diquet³, Sylvie Legrain^{4,5}, Marie-Geneviève Huisse^{4,6}, Alban Godon⁷, Corinne Bruhat⁸, Marie-Paule Chauveheid⁹, Sandrine Delpierre⁵, Xavier Duval^{1,2,10}, Gilles Berrut¹¹, Céline Verstuyft^{12,13}, Marie-Claude Aumont^{4,14}, France Mentré^{2,1}

¹ INSERM UMR738, University Paris Diderot, France

² Univ Paris Diderot, Sorbonne Paris Cité, Paris, France

³ Univ Angers PRES L'UNAM, Department Biology of the infectious agents and pharmacotoxicology, CHU Angers, France

⁴ Univ Paris Diderot, Sorbonne Paris Cité, Department of Medicine, Paris, France

⁵ AP-HP, Bretonneau Hospital, Department of Geriatrics, Paris, France

⁶ AP-HP, Bichat-Claude Bernard Hospital, Department of Haematology, Paris, France

⁷ Angers Hospital, Department of Haematology, Angers, France

⁸ Angers Hospital, Department of Geriatrics, Angers, France

⁹ AP-HP, Bichat-Claude Bernard Hospital, Department of Internal Medicine, Paris, France

¹⁰ AP-HP, Bichat-Claude Bernard Hospital, Centre of Clinical Investigation, Paris, France

¹¹ Nantes Hospital, Department of Clinical Gerontology, Nantes, France

¹² AP-HP, Hôpital Bicêtre, Service de Génétique moléculaire, Pharmacogénétique et Hormonologie, Le Kremlin Bicêtre, France

¹³ Univ Paris-Sud, EA4123, Le Kremlin-Bicêtre, France

¹⁴ AP-HP, Bichat-Claude Bernard Hospital, Department of Cardiology, Paris, France

Corresponding author: Dr Emmanuelle Comets
UMR 738 INSERM
Université Paris Diderot - Site Bichat
16 rue Henri Huchard
75018 Paris

email address: emmanuelle.comets@inserm.fr

telephone: (33) 1 5727 7535

fax : (33) 1 5727 7521

Abstract

In the PREPA observational study, we investigated the factors influencing pharmacokinetic and pharmacodynamic variability in the response to fluindione, an oral anticoagulant drug, in a general population of octogenarians inpatients.

Measurements of fluindione concentrations and INR (International Normalised Ratio) were obtained from 131 inpatients initiating fluindione treatment. Treatment was adjusted according to routine clinical practice. The data was analysed using non-linear mixed effect models, and the parameters were estimated using MONOLIX 3.2.

The pharmacokinetics of fluindione was monocompartmental, while the evolution of INR was modelled according to a turnover model (inhibition of vitamin K recycling). Interindividual variability was very large. Clearance decreased with age and with prior administration of cordarone. Patients who underwent surgery before the study had lower IC_{50} , leading to an increased sensitivity to fluindione.

Pharmacokinetic exposure is substantially increased in elderly patients, warranting a lower dose of fluindione.

Keywords: fluindione; antivitamin K; oral anticoagulant; elderly; pharmacokinetics; pharmacodynamics; International Normalised Ratio (INR)

Type of submission: Clinical Trial

Number of Tables: 3

Number of Figures: 5

Number of references: 50 / 50

Number of words in Text: 4989 / 5000

Number of words in Abstract: 139 / 150

1 Introduction

Evidence-based clinical practice guidelines recommend vitamin K antagonists in the prevention of stroke in atrial fibrillation [1, 2], in the treatment of venous thromboembolism [3], in patients with mechanical valve and in the first 3 months following bioprotheses implantation [4]. Despite their proven benefit, studies attest to their underutilisation particularly among elderly individuals [5, 6]. Antivitamin K agents (AVK) act by inhibiting the reduction reactions by which the vitamin K is recycled, in turn decreasing the synthesis of vitamine K-dependent coagulation factors (factors II (prothrombin), VII, IX, X, protein C, and protein S) [7]. The two main classes are coumarin derivatives, including warfarin and acenocoumarol, and indanedione derivatives, including fluindione and phenindione. Fluindione constitutes about 80% of AVK prescriptions in France [8].

AVK are characterised by a large between-, but also within-patient variability in the dose-response relationship. The therapeutic window is narrow, so that clinicians must walk a thin line between suboptimal dosage risking thromboembolic events and higher doses potentially risking bleeding episodes. The frequency and seriousness of haemorrhagic adverse events varies in the literature, depending on the population, the prescribed therapeutic range, the other treatments co-administered and the duration of treatment with AVK [9]. The Adverse Event Reporting system of the US Food and Drug Administration provides evidence that warfarin is among the top 10 drugs with the greatest number of serious adverse events. In France, where the present study was performed, iatrogenic events due to oral anticoagulant drugs represent the first cause of hospital admission for drug-related adverse event [10], totalling about 17000 admissions a year, and an estimated 3000 to 5000 deaths [11]. A meta-analysis of available clinical trials in patients anticoagulated for venous thromboembolism, reported a case-fatality rate of major bleeding of 13.4% in all patients (95% confidence interval 9.4 to 17.4%) [12]. Haemorrhagic events are overall more frequent and more severe in elderly patients compared to the general population [13]. The contribution of age *per se* to this increased risk is somewhat controversial, some studies pointing to an increase of the incidence of haemorrhagic events as a function of age [9] while others do not find it significant [14], but the fact that severity increases with age is undisputed [15] so that scores developed to predict the risk of bleeding include age over 65 as an independent risk factor [2, 16]. The main risk factors known to bring about haemorrhagic complications are level of anticoagulation, poor quality of monitoring, lack of patient education, associated comorbidities and comedications, including interactions with drugs interfering with haemostasis, and being in the first months of treatment [9, 14, 17]. Variability in International Normalised Ratio (INR) levels is also higher in elderly patients [18, 19]. A large part of this variability can be explained by changes in the dose-concentration relationship (pharmacokinetics, PK), or in the concentration-response relationship (pharmacodynamics, PD). Measurement of AVK

concentrations can contribute to a better understanding of these two components by separating these two contributions.

In the present paper, we describe the findings from the PREPA study, investigating the pharmacokinetics and pharmacodynamics of fluindione in octogenarians using non-linear mixed effect models. The primary objective of PREPA was to study the factors influencing the source of variability in the response to fluindione in elderly inpatients starting fluindione, with a special interest in comorbidities and comedications.

2 Results

2.1 Data

151 subjects were recruited in PREPA, 131 of whom provided PK/PD data and were included in the present PK/PD analysis. Table 1 shows the demographic and biologic variables recorded in this population.

The prescribed therapeutic range for INR was [2-3] for all the patients included in the study. The elderly patients included in the PREPA study were generally polymedicated: on the first day of the study, they received on average 8 different medications in addition to fluindione. In this study, initial dosing of fluindione was conservative: the initial dose was 5, 10 and 15-20 mg in 28, 94 and 10 subjects respectively. The median duration of stay in the study was 8 days (range 2 to 31 days). The last dose of fluindione was 5 mg or less for 32 subjects, 7.5-10 mg for 54 patients, 12.5-15 mg for 30 patients and 17.5-22.5 mg for 15 patients. There were large variations between the initial and final dose (correlation 0.25), with the dose unchanged in 44 subjects (34%) while 32 had a lower dose (24%) and 55 a higher dose (42%). This study was not designed to evaluate a maintenance dose of fluindione, and only 52 patients (40%) left the study with an INR between 2 and 3.

Ten subjects (8%) experienced bleeding during the study, as described elsewhere [20]. Nine of these patients also received heparin prior to initiating fluindione treatment, and severe bleeding occurred in 5 of them, always associated with the heparin treatment. The tenth subject, who suffered from hemorrhoids and constipation, started heparin on day 2 and experienced minor bleeding the next day, which resolved quickly.

2.2 Base model building

The PK dataset included 493 concentrations of fluindione, and the PD dataset 477 measurements of INR. A one-compartment model without lag-time provided an adequate fit to the PK data, based on tests and diagnostic graphs. Although the estimation error for the absorption rate constant k_a was reported as reasonable, its interindividual variability (IIV) was large, and

this parameter proved relatively unstable from run to run, especially at later stages when covariates were included in the model. Because there was little information about the absorption phase, we considered a model where k_a was fixed without variability. In a study in healthy volunteers, fludione was found to be quickly absorbed, with an average T_{max} of 2.0 h (range 0.5-6.0 h) [21], while the elimination half-life was 35 h (SD 6.5 h). Based on these figures, we fixed k_a to 2.42 hr^{-1} . This improved model stability, and provided similar estimates of V and CL. IIV was estimated for CL and V, without covariance.

An indirect response model for 1/INR was found adequate in the PK/PD analysis. INR values increase from baseline value of 1 in a normal patient, and the estimate of the additive part of the combined error model converged to a very small value. Therefore the residual variability for the INR model was modelled as proportional. A diagonal covariance matrix was used to model IIV. The Hill coefficient was significantly different from 1, and assuming a linear model instead of the I_{max} model also degraded the fit. Models including precursors were also tested to account for time delays but did not improve the fit or the likelihood.

2.3 Covariate model building

Covariates were first included on V and CL. Using the individual parameters estimates from the base model, the following covariates were found to have an influence on V, CL or both, and were considered for inclusion in the model: gender, weight, age, surgery, atrial fibrillation, renal function, Mini-Mental State (MMS) score, as well as administration of cordarone and deroxat. After pruning down the model, the following relationships remained: the volume of distribution V was found to increase with weight, and to be higher in men; clearance CL on the other hand was found to decrease with age, and to be lower in patients who received cordarone during the study. We also explored the relationships between parameters and time-varying comedications by considering each occasion as a separate subject. None of these comedications was found to influence the two PK parameters.

For the PD parameters, the following candidate relationships were found: CLCR, nonagerian, surgery and protamine on I_0 , deroxat on I_{max} , CLCR, surgery and protamine on k_{out} , nonagerian, surgery and protamine on C_{50} , Activities of Daily Living (ADL) score, surgery and deroxat on γ . In the final model, patients recovering from cardiac surgery were found to have reduced C_{50} and γ , translating to higher sensitivity. These patients were younger but age did not remain in the model. Deroxat increased γ .

The variability on I_{max} was poorly estimated and was removed from the final model. In most models we found I_0 to be very close to 1, but the assumption $I_0=1$ led to a significant increase in the statistical criterion.

2.4 Final model

Table 2 shows the parameter estimates for the base and final model (the range obtained by multiple imputation is given in Supplementary Table S2, showing the robustness of the estimates). There was a small decrease in the estimates of the variabilities of all parameters except k_{out} when including covariates in the model, however the IIV remained large. Relative standard errors were less than 10% for the main parameters, and within a 10-30% range for the variability of the random effects. Compared to women, men had an apparent volume of distribution increased by about 25%. The increase of V with weight was relatively small, since an increase of 10 kg in weight translates to about 9% increase in V . The decrease of CL with age is more relevant, since we expect a 90 year old patient to have a clearance reduced by 30% compared to a 80 year old patient, and patients who received cordarone had a 20% decrease in clearance. Prior surgery both increased the sensitivity to fluindione, reflected by a 50% reduction in IC_{50} , and decreased the sigmoidicity coefficient γ by about 50% so that the increase in the concentration-response curve is more gradual in these patients. The influence of deroxat on γ was the opposite, with a steeper curve for these patients indicating an on/off type of response.

We performed a small stability study to assess the ability of the sparse design to estimate the PK parameters, and found that CL and V could be correctly estimated (see Supplementary Material), consistent with the low correlations reported between the estimates of the PK parameters (-0.16 for the correlation between the estimates of V and CL). The correlations were higher between the PD parameters of the I_{max} model ($\text{corr}(IC_{50}, I_{\text{max}})=0.6$ and $\text{corr}(IC_{50}, \gamma)=-0.73$), suggesting that the design may not be as informative for the PD. All other correlations were lower than 0.35. The robustness of the estimates was checked by changing seeds and initial conditions. Shrinkage was large for most parameters, reflecting the relative lack of information in this sparse design: V (44%), CL (32%), IC_{50} (47%), k_{out} (63%), I_0 (86%) and γ (80%). The ϵ -shrinkage was 31% for PK and 39% for PD.

Diagnostic plots are shown in figures 2 and 3. Graphs of the npde (normalised prediction distribution errors) versus time and dose, which are more appropriate than VPC because of the heterogeneous design [22, 23], are shown in Figure 3; prediction bands have been overlayed to indicate model predictions. The two upper graphs show the npde versus time, for fluindione (left) and INR (right), and indicate good model adequacy for fluindione, while for INR the model slightly underpredicts the last time-point. The two lower graphs show the npde versus model predictions; the model can be seen to perform adequately on average both for PK and PD, while variability is sometimes under or overestimated. Individual graphs are shown for 12 subjects from different clinical departments (Figure 4: fluindione concentrations; Figure 5: INR). The dotted line in the individual plots for INR show the target therapeutic range, while vertical bars are drawn to show the doses received (the scale for doses is on the right-hand axis). For most

subjects, the model is able to reproduce both PK and PD measurements adequately, describing even complex profiles. In a few cases, (eg subject 1086, topmost panel, right), the PK is very well predicted but the PD shows unexplained fluctuations, with INR starting to decrease despite stable doses and concentrations.

Using the steady-state approximation with the population parameters, we found that doses of 7.5 and 10 mg ensure an INR within the therapeutic range for a typical patient (weight 65 kg, age 85 kg), regardless of gender. IIV however is large, and often at least 2 doses provide an INR within the range. Table 3 shows dose recommendations depending on individual covariates, obtained by simulations under the model. In each setting, when taking into account IIV, this average dose is valid in about 20% of the simulations, while a dose within ± 2.5 mg of this dose is recommended in about 50% of the simulations.

3 Discussion

Fluindione is an AVK used mostly in France, where it is regarded as an interesting alternative to the warfarin; contrary to warfarin, fluindione is not a racemic mixture and its longer half-life is considered to help stabilise INR levels [24]. As other anticoagulant drugs however, it is a difficult drug to adjust. In a previous study called ADAP, we investigated the pharmacokinetics and pharmacodynamics of fluindione in a general population of patients initiating treatment [25, 26]. In these younger patients (mean 60 years, range 29–89), we demonstrated not only large IIV, but also, through a follow-up study recording dose changes and evolution of anticoagulation after discharge from the hospital, a sizeable intraindividual variability. This variability led to fluctuations in the anticoagulation level even in patients thought to be stabilised when leaving the hospital [27].

In the present study, we used a PK/PD model closely related to the one developed in ADAP. The main differences are the absorption model, which was previously assumed to a bolus dose and which we fixed here, and the use of a Hill model to represent drug effect. The estimates of CL and V were very close to the value estimated assuming an IV bolus, but the statistical criterion was slightly better with an oral absorption phase. The estimates of the PK parameters however are quite different from previously [25, 26]. In the final model, V was estimated to be around 8 L, while CL was $0.1 \text{ L}\cdot\text{hr}^{-1}$. In the ADAP study on the other hand, we estimated these parameters to be respectively 37 L and $0.49 \text{ L}\cdot\text{hr}^{-1}$. Both sets of parameters however give the same estimate for half-life, 56 h versus 52 h previously. The increased exposure was also apparent in the measured concentrations: in the ADAP study, subjects received daily doses of fluindione, with starting doses of 15 to 20 mg, and concentrations after 5 days of treatment were around 0.8 to $1.2 \text{ mg}\cdot\text{L}^{-1}$, while in PREPA concentrations at day 5 range from 1 to over $8 \text{ mg}\cdot\text{L}^{-1}$ as shown in figures 1 and 4. In addition, starting doses were lower, most patients receiving

10 mg initially or less. Thus, compared to the previous study, we observe a marked increase in the exposure to fluindione. Since fluindione is administered orally, the reported V and CL are apparent parameters, so an explanation to this discrepancy with previous results is a difference in bioavailability between the two studies. However, this would require a more than four-fold increase in bioavailability in elderly patients compared to the younger population previously studied. Fluindione is to some extent cleared by the liver, with the hepatic metabolism of fluindione appearing to be mediated by CYP2C9 [28], but is mainly renally excreted, so that we do not expect first-pass effect to be a major determinant of drug concentrations; the increase in drug exposure would then be driven by a dramatic increase in the absorption process. Changes in plasma protein binding could be another possibility. For all drugs eliminated primarily by the liver total exposure is independent of protein binding but, like fluindione, oral drugs eliminated by nonhepatic high extraction ratio routes exhibit changes in unbound drug exposure when protein binding changes. This would not be expected to affect exposure to such an extent since fluindione does not exhibit a particularly high extraction ratio [29]. The smaller volume of distribution might be the consequence of the combination of a lowered volume of tissue with an increase of the fraction unbound in tissue ($V=V_p + V_t f_u/f_{ut}$), both clinically relevant in an elderly population with a lipophilic drug [30]. Modification, either increase or decrease, of transit times in this heavily medicated population could also explain an increase in the fraction absorbed by changing the dissolution of fluindione; indeed, 117 patients (89%) received drugs modifying transit, and slower intestinal transit times are frequently observed in the elderly. The alteration in PK exposure could therefore be due to a combination of factors [30] and warrants further exploration in a controlled study.

Dose reduction with age is also observed for other oral anticoagulants [18, 24]. The latter study, although admittedly retrospective, included over 22 000 patients, and found that patients aged 80 years or older required doses one-third to one-half of those given to patients younger than 50. For fluindione, Mahé et al. observed in a retrospective study that patients over 75 years old required a lower dose of fluindione than younger patients for a comparable INR [31], which can be interpreted as due to modifications in exposure in the light of our results. For the PD parameters, we found an estimate of IC_{50} about 60% higher than in the ADAP study ($2.18 \text{ mg}\cdot\text{L}^{-1}$ instead of $1.35 \text{ mg}\cdot\text{L}^{-1}$), but still within the same range, suggesting that elderly patients have a similar sensitivity to fluindione despite having an increased exposure. The present study provides a rationale explaining the findings of others that lower doses are required in elderly patients, by linking them to PK, and underscores the importance of having both PK and PD measurements in order to separate pharmacokinetic and pharmacodynamic changes. k_{out} on the other hand was noticeably smaller (0.03 versus 0.18 hr^{-1}), indicating a slower turnover than in younger patients.

We used the model and parameter estimates to predict a dose that should be given in order to

maintain an INR within the therapeutic range at steady-state. Consistent with the observation that the concentrations were higher in this population of elderly patients than in the population we previously studied [25, 26], the model predicted relatively low doses, suggesting a daily 10 mg dose, or an alternance of 5 and 10 mg doses, should be a safe starting dose for most patients. This is also in line with the maintenance doses observed in the retrospective study by Mahé [31]. Fluindione however is still packaged as 20 mg pills, which are in practice difficult to divide for routine treatment.

The present study was targeted towards elderly patients during hospitalisation, since this population is both more likely to receive anticoagulant drugs and more fragile, being often polymedicated and with comorbidities. These patients are therefore more susceptible to bleeding and dose adjustment for oral anticoagulants is particularly difficult [32]. Given its observational nature and the short duration, the PREPA study was not specifically designed to investigate risk factors for clotting or bleeding; a more detailed analysis of the 8 bleeding events which occurred in the subset of patients with atrial fibrillation can be found in [20]. A major objective of the present study was to identify covariates that could explain some of the variability in the response. We found the pharmacokinetic parameters to be influenced by gender, weight and age, as well as prior administration of cordarone (amiodarone) while the only covariates influencing pharmacodynamic parameters were prior surgery and administration of deroxat. We did not find any relationship with time-varying comedications, but this may be due to the heterogeneity of the population and to the small sample size. Cordarone has been reported to increase the haemorrhagic risk [33], which could relate to the 20% reduction we find, translating into an increased exposure. We did not find a relationship with anti-infective agents (antibiotics and anti-fungal drugs) as in that study; nearly half of the patients received an antibiotic at some point during treatment, but it is possible that the analysis could not pick up a relationship especially if the influence is delayed, since we considered only an on/off type of relationship. Also the sample size was too small to consider each drug separately so we pooled the different antibiotics and the different dosages for the analyses. About a third of the patients took part in the optional pharmacogenetic study. We found no relationship between the 3 genetic polymorphisms and PK or PD parameters. The influence of CYP2C9 on PK through metabolism has been described for warfarin [34]; for fluindione, a recent study in healthy volunteers showed a lower clearance in carriers of the *3 allele [28], while the influence on the response is expected to be related to VKORC1 [35, 28]. We were not able to confirm these relationships here, perhaps due to the small number of subjects.

Most patients did not remain in the study long enough to reach a stable INR. However, even within the duration of their stay, we noted that dose changes occurred too often and sometimes irrationally. In particular, the long time-course of INR evolution after AVK did not appear well anticipated by the prescribing clinicians. This is apparently partly due to a lack of follow-up,

as doses are frequently modified based only on the latest INR, without considering the pattern of doses given and INRs measured since the beginning of the treatment. In several countries specialised anticoagulation clinics have been set up to help manage anti-vitamin K drugs and have been shown to improve management of anticoagulation treatment [8]; a pilot clinic now exists in France [36]. A perspective of the present work could be to develop a software helping clinicians to anticipate the future evolution of anticoagulation, by producing plots based on individual INR measurements and dosing regimen [37, 38].

In conclusion, the PREPA observational study highlighted that dose adjustment for AVK agents is still a major issue, especially in the elderly. The complexity of INR dynamics and the resulting delay between the time-course of the drug and the clinical variations of anticoagulation levels make it difficult to anticipate changes in INR, so that adjustments in doses must be made after taking into account the evolution over several days and not a single measurement. Elderly patients should be treated as a special population presenting a noticeably increased pharmacokinetic exposure to the drug. They should receive significantly lower doses and the onset of treatment should remain conservative.

4 Methods

4.1 Data

The PREPA study was a prospective, observational multicenter study conducted between September 2005 and September 2007, recruiting consecutive patients hospitalised in 6 medical and 1 surgical (cardiac) acute-care units from 3 French hospitals. Patients, 80 or older, were prescribed fluindione after at least 2 weeks off oral anticoagulants. Exclusion criteria were: contraindication to fluindione treatment due to hypersensitivity to indanedione derived drugs, incompatible comedication, inclusion in another therapeutic trial, expected length of stay in hospital less than 3 days. The study was approved by the Ethics committee from Hospital Européen Georges Pompidou (HEGP), and all participants provided written informed consent in accordance with the Declaration of Helsinki. The clinical trial has been registered on the public registry ClinicalTrials.gov.

Patients were followed by clinicians according to the local clinical practices. In particular, doses were adjusted based on routine measurements of INR, without using any dosing algorithm. Fluindione was administered in the evening, usually around 6 p.m. Blood samples for the measurement of INR were taken in the morning, according to the usual practice in the participating centers for therapeutic monitoring: before the first administration of fluindione (day 0), and after 2, 4, 6 and 8 doses of fluindione; additional samples were obtained twice a week after that for therapeutic monitoring. The date of each sample was recorded by the nurse, and the time of the sample when it was outside of the window 9-11 a.m. Each time a blood sample was

taken for the measurement of INR and coagulation factors, an additional 5 mL blood vial was drawn for measuring fluindione concentrations, except at day 0, where fluindione concentrations were measured only in patients who had received a dose of an oral anticoagulant within the two weeks immediately preceding the first dose of fluindione in the study. As an ancillary optional study, which required a separate informed consent, an additional blood sample was taken for genotyping. Genetic polymorphisms for two CYP2C9, which are known to influence the pharmacokinetics of warfarin [34] and acenocoumarol [35], as well as a genetic polymorphism in the gene coding for vitamin K epoxide reductase complex subunit 1 (VKORC1) [39], the target of AVK treatment and involved in the response [40], were determined. Analytical details are available in the Supplementary material.

For each patient, the following variables were recorded at the inclusion visit by a clinician involved in the study: age, gender, weight, weight changes within the 6 months preceding the inclusion visit, ADL, Charlson comorbidity score, MMS, reason for fluindione treatment, therapeutic range for INR, major comorbidities, cardiac surgery. A number of biological variables were also measured at baseline: albumin, C-reactive protein (CRP), haematocrit levels, prothrombin, natremia. Creatinine clearance (CRCL) was computed from age (year) and creatinine clearance using the following formula [41]:

$$\text{CRCL}_{\text{MDRD}}(\mu\text{mol/l}) = 186 (0.0113 \text{ CREAT})^{-1.154} \text{ Age}^{-0.203} \quad (1)$$

Renal function was classified as normal ($\text{CLCR} \geq 60$ ml/mn), moderately impaired (CLCR between 30-60 ml/mn) and severely impaired ($\text{CLCR} < 30$ ml/mn).

Patients were defined as suffering from malnutrition when they had recent severe weight loss (over 10% of weight), a body mass index lower than 18, or albumin levels lower than 30. Finally, high levels of CRP ($\text{CRP} > 50$ mg.L⁻¹) were considered to be a sign of current hypercatabolism.

One important objective in this group of elderly inpatients was to describe and take into account the many comedications these patients received. Comedications given to each patient were recorded at the initial visit, and changes were documented throughout the study. Comedications received were classified according to their influence on INR, using the classification proposed by Holbrook [42] (given in Supplementary Table S2). Drugs were first classified according to whether they increase the thrombotic risk or the haemorrhagic risk; the second group was divided further into drugs increasing the INR (class B2) versus drugs acting independently (class B1). Nonsteroidal anti-inflammatory drugs (group B12) and diuretics were also considered for their potential effect on pharmacokinetic parameters. For each class and each subject, we defined a daily indicator variable. Cordarone, amiodarone and deroxat, because of their long half-life, were considered separately and assumed to remain active for 1 month (cordarone and amiodarone) and 15 days (deroxat). Only therapeutic classes which were received by at least 10 and at most 122 patients were considered in the analysis.

4.2 Model building

Non-linear mixed effect models were used in this analysis; the j th observation in subject i , y_{ij} , is modelled as:

$$y_{ij} = f(x_{ij}, \psi_i) + g(x_{ij}, \psi_i)\epsilon_{ij} \quad (2)$$

where ψ_i denotes the individual parameters, f the structural model and g the residual error model ($\epsilon_{ij} \sim \mathcal{N}(0, 1)$). We assume that ψ_i depends on individual covariates c_i , a vector of fixed effects μ and a vector of individual random effects η_i through a function h :

$$\psi_i = h(\mu, c_i, \eta_i) \quad (3)$$

The parameters were estimated through the Stochastic Approximation EM algorithm (SAEM) implemented in the MONOLIX software [43] (version 3.2, release 1), running on a Linux PC (Kubuntu 10.10). All other statistical analyses were performed in R (2.11) [44].

Base model selection. We first studied the PK of fluindione alone. The residual variability was modelled using a combined error model. The structural model was built by selecting the best model amongst one and two-compartmental models with first or zero-order absorption, with or without lag-time.

The evolution of INR was modelled using a turnover model, describing the evolution of coagulation factor activity $F(t) = 1/INR(t)$ through the following equation:

$$\frac{dF(t)}{dt} = R_{\text{syn}} \left(1 - I_{\text{max}} \frac{C(t)^\gamma}{C(t)^\gamma + IC_{50}^\gamma} \right) - k_{\text{out}} F(t) \quad (4)$$

The model was parameterised in terms of k_{out} and $INR_0 = 1/F_0$ where, in the absence of drug, we have the relationship: $F_0 k_{\text{out}} = R_{\text{syn}}$.

I_{max} was assumed to follow a logit distribution while all the other parameters had a log-normal distribution. For each parameter we tested whether IIV could be removed from the model, and we also tested correlations between parameters by introducing covariances. To select structural and variability models, we used appropriate likelihood ratio tests (LRT), based on the log-likelihood computed using importance sampling.

Covariate model building. We examined the relationships between parameters and covariates, first in the PK model alone, then in the PK/PD model. Covariate model building was done by exploring the relationships between covariates and estimated individual parameters (obtained as the conditional modes of the individual distribution) through linear regression for the continuous covariates and parametric tests for the categorical covariates; all candidate covariates were included in a full model, using power functions for continuous covariates; the model was then pruned down by removing covariate effects for which the p-value of the Wald test was larger

than 0.05, starting with the covariates which had the largest p-value. A non-significant Wald test indicates a high estimation error for the corresponding parameter. The same approach was used for the full PK/PD model with the best PK model, re-estimating all parameters. The final PK/PD model was evaluated using standard diagnostic graphs provided by MONOLIX. We also computed the shrinkage, as, for the k th- parameter:

$$\text{Sh}_k = 1 - \frac{\text{var}(\hat{\eta}_i^{(k)})}{\omega_k^2} \quad (5)$$

where $\hat{\eta}_i^{(k)}$ is the estimated k th random effect in subject i . The ϵ -shrinkage was computed separately for PK and PD:

$$\text{Sh}_\epsilon = 1 - \text{var}(\text{IWRES}_{ij}) \quad (6)$$

where IWRES denotes the individual weighted residuals. In the presence of high shrinkage, diagnostic plots based on individual estimated parameters are less informative [45].

Covariates missing in more than 14 subjects (10%) were excluded from the analysis; the other missing covariates were imputed to the mean value for continuous variables and to a value randomly sampled for the discrete covariates. The final model was checked using multiple imputation [46], using the package mice for R [47]. An additional exploratory analysis investigated relationships between the PK/PD parameters and the genetic covariates in subsets of the data.

Steady-state dose. Fluindione is provided as 20 mg tablets, which can be cut in four 5 mg pieces; dosage is often alternated (eg 10 mg one day and 5 the next). An estimate of the steady-state dose for a given patient can be obtained through the following equations, where C_{ss} denotes the average concentration that would be obtained for regular doses given every 24 hours, and INR_{ss} denotes the steady-state INR that would be reached assuming the concentration remained equal to C_{ss} :

$$C_{\text{ss}} = \frac{D}{24 \text{ CL}}$$

$$\text{INR}_{\text{ss}} = \frac{I_0}{\left(1 - \frac{I_{\text{max}}}{1 + \left(\frac{24 \text{ CL IC}_{50}}{D}\right)^\gamma}\right)}$$

We used the second equation to predict INR_{ss} given a set of PK/PD parameters, for doses ranging from 2.5 to 30 mg per day; a dose was considered to be adequate if INR_{ss} was within the desired therapeutic range of 2-3. We also defined a recommended dose by using 1000 Monte-Carlo simulations taking into account IIV; for each simulation, the recommended dose was the dose yielding the INR_{ss} closest to 2.5. An associated probability is the percentage of simulations recommending that dose.

Acknowledgments

This study was supported by a grant from the Groupement d'Intérêt Scientifique (GIS) Longévit , and the genotyping analyses were financed by a grant from the Comit  d'Orientation Strat gique et de Suivi des Essais Cliniques (COSSEC, INSERM, Paris, France). The promoter of the study was the Institut de la Sant  et de la Recherche M dicale (INSERM, Paris, France).

Estelle Mottez (INSERM) was instrumental in taking care of the promotion of the study. The Centre d'Investigation Clinique (CIC) of the Bichat hospital (Paris, France) kindly ensured the monitoring of the study. We would like to thank in particular Dr Hayk Papayan and Val rie Vignali for their involvement in the study follow-up. We would also like to thank the Centre de Ressources Biologiques (CRB Bichat) and especially Dr Jo lle Benessiano for taking care of the DNA samples. Finally, we would like to thank the nursing staff who ensured daily sample collection and the staff from the different analytical departments involved in the study.

Conflict of interest/Disclosure

None

References

- [1] Lip G., Hart R. & Conway D. Antithrombotic therapy for atrial fibrillation. *Br. Med. J.* **325**, 1022–25 (2002).
- [2] European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm A., Kirchhof P., Lip G. & Schotten U. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). *Eur. Heart J.* **31**, 2369–429 (2010).
- [3] Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E. & Comerota A.J. Antithrombotic therapy for venous thromboembolic disease. (American College of Chest Physicians evidence-based clinical practice guidelines, 8th edition). *Chest* **133**, 454S–545S (2008).
- [4] Vahanian A. et al. Guidelines on the management of valvular heart disease: The task force on the management of valvular heart disease of the European Society of Cardiology. *Eur. Heart J.* **28**, 230–68 (2007).
- [5] Hart R., Benavente O., Mc Bride R. & Pearce L. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann. Intern. Med.* **131**, 492–501 (1999).
- [6] Lagerstedt C., Olsson C., Fagher B., Oquist B. & Albrechtsson V. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. *Lancet* **2**, 515–18 (1985).
- [7] Holford N. Clinical pharmacokinetics and pharmacodynamics of warfarin. understanding the dose–effect relationship. *Clin. Pharmacokinet.* **11**, 483–504 (1986).
- [8] Ansell J., Hollowell J., Pengo V., Martinez-Brotons F., Caro J. & Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). *J. Thromb. Thrombolysis* **23**, 83–91 (2007).
- [9] Levine M., Raskob G., Landefeld S. & Kearon C. Hemorrhagic complications of anticoagulant treatment. *Chest* **119**, 108s–21s (2001).
- [10] Pouyanne P., Haramburu F., Imbs J. & Bégau B. Admissions to hospital caused by drug reactions : cross sectional incidence study. *Br. Med. J.* **320**, 1036 (2000).
- [11] Agence Française de Sécurité Sanitaire des Produits de Santé. [good management practices for oral anticoagulant overdose, situations of hemorrhagic risk and hemorrhagic events in patients taking oral anticoagulants in the ambulatory and hospital setting]. *J. Mal. Vascul.* **33**, 202–13 (2008).

- [12] Linkins L., Choi P. & Douketis J. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. *Ann. Intern. Med.* **139**, 893–900 (2003).
- [13] Hutten B., Lensing A., Kraaijenhagen R. & Prins M. Safety of treatment with anticoagulants in the elderly. A systematic review. *Drugs Aging* **14**, 303–12 (1999).
- [14] Ansell J., Weitz J. & Comerota A. Advances in the therapy and the management of antithrombotic drugs for venous thromboembolism. *Hematology* **23**, 266–84 (2000).
- [15] Fihn S., Callahan C., Martin D., Mc Donnell M., Heniko J. & White R. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. *Ann. Intern. Med.* **124**, 970–9 (1996).
- [16] Palareti G. & Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. *Thromb. Haemost.* **102**, 268–78 (2009).
- [17] Evans A., Davis S., Kilpatrick C., Gerraty R., Campbell D. & Greenberg P. The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. *J. Clin. Neurosci.* **9**, 268–72 (2002).
- [18] Hylek E. Oral anticoagulants. Pharmacological issues for the elderly. *Clin. Geriatr. Med.* **17**, 1–13 (2002).
- [19] Hylek E., Regan S., Go A., Hughes R., Singer D. & Skates S. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. *Ann. Intern. Med.* **135**, 393–400 (2001).
- [20] Bonnet-Zamponi D. *et al.* Heparin bridging therapy and bleeding events in octogenarians inpatients with atrial fibrillation starting anticoagulation: Results of an ancillary study. *J. American Geriatr. Soc.* (2011, in press).
- [21] Warot D. *et al.* Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. *Fundam. Clin. Pharmacol.* **14**, 231–6 (2000).
- [22] Brendel K., Comets E., Laffont C., Laveille C. & Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. *Pharm. Res.* **23**, 2036–49 (2006).
- [23] Comets E., Brendel K. & Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. *Comput. Methods Programs Biomed.* **90**, 154–66 (2008).

- [24] Fihn S. *et al.* Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. *Thromb. Haemost.* **90**, 260–6 (2003).
- [25] Mentré F. *et al.* Population pharmacokinetic–pharmacodynamic analysis of fluindione in patients. *Clin. Pharmacol. Ther.* **63**, 64–78 (1998).
- [26] Comets E. *et al.* Modeling INR data to predict maintenance fluindione dosage. *Ther. Drug Monit.* **20**, 631–639 (1998).
- [27] Comets E. *et al.* Prediction of fluindione maintenance dosage hampered by large intraindividual variability. *Ther. Drug Monit.* **22**, 668–75 (2000).
- [28] Verstuyft C. *et al.* A PK-PD model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. *Clin. Pharmacol. Ther.* (2011, in press).
- [29] Benet L. & Hoener B.A. Changes in plasma protein binding have little clinical relevance. *Clin. Pharmacol. Ther.* **71**, 115–21 (2002).
- [30] Currie G., Wheat J. & Kiat H. Pharmacokinetic considerations for digoxin in older people. *Open Cardiovasc. Med. J.* **5**, 130–5 (2011).
- [31] Mahé I., Grenard A.S., Joyeux N., Caulin C. & Bergmann J.F. Management of oral anticoagulant in clinical practice: a retrospective study of 187 patients. *J. Gerontol. A. Biol. Sci. Med. Sci.* **59**, 1339–42 (2004).
- [32] Vogel T., Coriol V., Kaltenbach G., Kiesmann M. & Berthel M. [Prospective study of oral anticoagulation control in 110 very elderly hospitalized patients and of risk factors for poor control] [Article in French]. *Presse Med.* **37**, 1723–30 (2008).
- [33] Siguret V., Esquirol C., Debray M., Gouin I., Andreux J.P. & Pautas E. [Excess antivitamin k in elderly hospitalised patients aged over 70. a one-year prospective survey] [Article in French]. *Presse Med.* **32**, 972–7 (2003).
- [34] Aithal G.P., Day C.P., Kesteven P.J.L. & Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. *Lancet* **353**, 717–9 (1999).
- [35] Verstuyft C. *et al.* Genetic and environmental risk factors for oral anticoagulant overdose. *Eur. J. Clin. Pharmacol.* **58**, 739–45 (2003).
- [36] Lévesque H. & Borg J.Y. [Anticoagulant clinic: a tool for reduce bleeding complications of oral anticoagulant treatment] [Article in French]. *Rev. Med. Intern.* **24**, 75–7 (2003).

- [37] Manotti C., Moia, Palareti G., Pengo V., Ria L. & Dettori A. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated Program for Oral Anticoagulant Treatment). *Haematologica* **86**, 1060–70 (2001).
- [38] Saint-Marcoux F., Vandierdonck S., Prémaud A., Debord J., Rousseau A. & Marquet P. Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. *Ther. Drug Monit.* **33**, 285–94 (2011).
- [39] Rost S. *et al.* Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. *Nature* **427**, 537–41 (2004).
- [40] Bodin L. *et al.* Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. *Blood* **106**, 135–40 (2005).
- [41] Levey A. *et al.* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Ann. Intern. Med.* **16**, 461–70 (1999).
- [42] Holbrook A.M. *et al.* Systematic overview of warfarin and its drug and food interactions. *Arch. Intern. Med.* **165**, 1095–106 (2005).
- [43] Lavielle M. *MONOLIX (MOdèles NON Linéaires à effets miXtes)*. MONOLIX group, Orsay, France (2005).
URL <http://www.math.u-psud.fr/~lavielle/programs/monolix.pdf>
- [44] R Development Core Team. *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria (2004).
URL <http://www.R-project.org>
- [45] Karlsson M. & Savic R. Diagnosing model diagnostics. *Clin. Pharmacol. Ther.* **82**, 17–20 (2007).
- [46] Little R. & Rubin D. *Statistical analysis with missing data* (John Wiley & Sons, Inc., Hoboken, New Jersey, 2002), 2nd edn.
- [47] van Buuren S. & Groothuis-Oudshoorn K. MICE: Multivariate imputation by chained equations in R. *J Stat Soft* (2010, in press).
- [48] Aymard G., Legrand M., Comets E., Mentré F. & Diquet B. Rapid and simple micromethod for the quantification of fluindione in human plasma using high-performance liquid chromatography. *J Chromatogr B* **707**, 169–173 (1998).

- [49] Rieder M.J. *et al.* Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *N. Engl. J. Med.* **352**, 2285–93 (2005).
- [50] Lacut K. *et al.* Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH study. *J. Thromb. Haemost.* **5**, 2020–4 (2007).

List of Figures

Figure 1: PKPD data collected in the 131 patients from the PREPA study: (top) concentration of fluindione versus time in the study (in days); (bottom) INR versus time in the study. Dotted lines delineate the therapeutic range for the patients in PREPA (2-3).

Figure 2: Goodness-of-fit plots: (top) observed versus predicted fluindione concentrations; (bottom) observed versus predicted INR. The plots on the left were obtained with population parameter estimates, while the plots on the right were obtained with individual parameter estimates. The solid line represents the unity line around which points are expected to scatter evenly.

Figure 3: Goodness-of-fit plots: npde with prediction intervals, for fluindione (left) and INR (right) versus time (top) and predictions (bottom). The blue areas correspond to the prediction intervals for the median (central band) and for the limits of the 95% prediction interval; the thin dotted lines represent the predictions of the median and the limits, while the thick red lines show the corresponding observed values.

Figure 4: Individual fits for 12 subjects, fluindione concentrations. Patient numbers starting with 1 indicate patients recruited in the cardiology department, with 3 or 4 one of the two geriatric departments, and with 5 the internal medicine department.

Figure 5: Individual fits for the same subjects, INR, superimposed with the daily dosing pattern as vertical bars (scale for doses are on the right-hand axis).

Table 1 : Demographic and biologic variables in the 131 patients from the PREPA study.

Variable	Median	(range)	
Age (yr)	85	(80-98)	
Weight (kg, missing N=14)	65	(32-112)	
ADL (-, missing N=6)	5.5	(1.5-6.5)	
Creatinine clearance (ml/mn, missing N=3)	68	(11-179)	
Gender	Women: 87 (66%)	Men: 44 (34%)	
Surgery (cardiac surgery before fluindione treatment)	Yes: 52 (40%)	No: 79 (60%)	
Indication for fluindione			
Atrial fibrillation	84 (64%)		
Venous thromboembolism	27 (30%)		
Heart valve prosthesis	43 (33%)		
Most frequent comorbidities			
Congestive heart disease	79	(60%)	
Renal impairment	50	(38%)	
Chronic pulmonary disease	28	(21%)	
Peripheral vascular disease	22	(17%)	
Diabetes	20	(15%)	
Albumin (missing N=65)	Normal (> 35): 29	30-35: 18	<30: 19
CRP (missing N=68)	Normal (< 5): 13	5-50: 29	50-100: 13
	≥ 100: 8		
Absolute weight loss (missing N=14)	2-5 kg: 24	Over 5 kg: 21	
Malnutrition (missing N=1)	Yes: 27	No: 103 ¹	
Renal function (missing N=16)	Normal: 27	Moderate: 66	Severe: 22
CYP2C9 *2 (missing N=86)	Wild: 32	Het: 12	Mut: 1
CYP2C9 *3 (missing N=91)	Wild: 31	Het: 7	Mut: 2
VKORC1 (missing N=89)	CC: 11	CT: 21	TT: 10

¹ for 76 subjects classified as not suffering from malnutrition and 10 with malnutrition, one or several of the variables used to define malnutrition were missing and assumed normal

Table 2 : Parameter estimates for the PK/PD model without covariate (base model) and for the final model. Interindividual variability is given as coefficient of variation (CV), and the relative estimation error (RSE) is also shown.

Parameter	Base model		Final model	
	Mean (RSE %)	CV % (RSE %)	Mean (RSE %)	CV % (RSE %)
k_a (hr^{-1})	2.42 (-)	-	2.42 (-)	-
V (L)	9.06 (5)	41 (10)	8.24 (5)	36 (10)
$\beta_{V,\text{men}}$	-	-	0.24 (41)	-
$\beta_{V,\text{weight}}$	-	-	0.57 (35)	-
CL ($\text{L}\cdot\text{hr}^{-1}$)	0.12 (5)	47 (8)	0.10 (8)	42 (8)
$\beta_{CL,\text{age}}$	-	-	-3.26 (30)	-
$\beta_{CL,\text{cordarone}}$	-	-	-0.18 (49)	-
I_0 (-)	1.11 (2)	10 (21)	1.10 (2)	7 (31)
k_{out} (hr^{-1})	0.03 (14)	80 (15)	0.03 (13)	85 (13)
IC_{50} ($\text{mg}\cdot\text{L}^{-1}$)	1.71 (10)	56 (10)	2.18 (11)	53 (10)
$\beta_{IC_{50},\text{surgery}}$	-	-	-0.54 (25)	-
I_{max} (-)	0.89 (6)	-	0.94 (7)	-
γ (-)	1.70 (15)	53 (16)	1.71 (15)	40 (21)
$\beta_{\gamma,\text{surgery}}$	-	-	-0.46 (34)	-
$\beta_{\gamma,\text{deroxat}}$	-	-	0.88 (31)	-
a_{PK} ($\text{mg}\cdot\text{L}^{-1}$)	0.19 (15)	-	0.20 (14)	-
b_{PK} (-)	0.09 (16)	-	0.08 (17)	-
b_{PD} (-)	0.14 (5)	-	0.13 (5)	-

Removed: ¹ weight was centered on 60 kg

Removed: ² age was centered on 90 yr

The following parameter-covariate relationships were estimated, with i denoting the individual:

$$\begin{aligned}
 V_i &= V \left(\frac{\text{WEIGHT}_i}{60} \right)^{\beta_{V,\text{weight}}} \text{Men}_i^{\beta_{V,\text{men}}} e^{\eta_{V,i}} \\
 CL_i &= CL \left(\frac{\text{AGE}_i}{90} \right)^{\beta_{CL,\text{age}}} \text{Cordarone}_i^{\beta_{CL,\text{cordarone}}} e^{\eta_{CL,i}} \\
 IC_{50,i} &= IC_{50} \text{Surgery}_i^{\beta_{IC_{50},\text{surgery}}} e^{\eta_{IC_{50},i}} \\
 \gamma_i &= \gamma \text{Surgery}_i^{\beta_{\gamma,\text{surgery}}} \text{Deroxat}_i^{\beta_{\gamma,\text{deroxat}}} e^{\eta_{\gamma,i}}
 \end{aligned} \tag{7}$$

where for instance Men_i is 1 if i is a man and 0 if a woman. Weight was centered on 60 kg, while age was centered on 90 yr.

Table 3 : Recommended dose depending on different patient profiles, defined as the dose yielding a steady-state value closest to 2.5. The last column represents the percentage of time that the corresponding dose is selected over the 1000 Monte-Carlo simulations performed, to take into account the IIV.

Profile	Recommended dose (mg)	Probability
80 year old man, 60 kg	7.5	17%
80 year old woman, 60 kg	7.5	17%
80 year old man, 50 kg	7.5	16%
80 year old man, 70 kg	10	17%
90 year old man, 60 kg	5	22%
80 year old man, 60 kg, after cardiac surgery	5	24%
80 year old man, 60 kg, given cordarone	5	22%
80 year old man, 60 kg, given deroxat	5	19%

Figure 1 :





Figure 2 :




Figure 3 :







Figure 4 :





Figure 5 :



Supplementary material

Analytical methods

Analytical methods. For patients recruited in the Bichat and Angers university hospitals, INR was assayed on-site in the corresponding Laboratoire d'Hémostase, which both use a STARE coagulometer (Diagnostica Stago, 92600 Asnières, France) and thromboplastin STA[®]-Neoplastin CI with an international sensitivity index (ISI) of 1.63 (batch number 100675, Diagnostica Stago) during the whole study. The samples from the 4 patients in the Beaujon hospital were centralised at the Bichat hospital. INR was calculated from the prothrombin time (PT) as:

$$\text{INR} = \left(\frac{\text{Patient PT}}{\text{mean normal PT}} \right)^{\text{ISI}} \quad (8)$$

The two Laboratoires d'Hémostase both perform routine controls, which included for the study period successively C06, C07, C08 (Asqualab, Stago) that were daily checked on the coagulometer. PT coefficient of variation was between 1.7-2.4% during this period.

Determination of fluindione concentrations. The samples for the measurement of fluindione concentrations were frozen at -20°C, and shipped at regular intervals throughout the study to the Laboratoire de Pharmacologie-Toxicologie in the Angers university hospital. Plasma fluindione was assayed with use of an HPLC–UV system Surveyor (ThermoFinnigan), with ChromQuest software [48]. The UV spectrophotometer was set at a wavelength of 280 nm. The separation was achieved at 40°C temperature, with a reversed-phase 100X 4.6 mm internal diameter BetaBasic-8 column and 5 µm particle size packing (ThermoElectron). The mobile phase composition was optimized to a 0.067 mol.L⁻¹ dibasic sodium phosphate buffer (adjusted to pH 6.3 with phosphoric acid) and acetonitrile (82:18, vol/vol) mixture. The flow rate was set at 1.5 mL.min⁻¹. The following extraction procedure was used: 100 µL of plasma from human heparinized blood (spiked plasma used for calibration and controls; patients' plasma samples) was added to a 1.5 ml tube that contained 50 µL of 20 mg.L⁻¹ internal standard solution (warfarin) and 100 µL acetonitrile. The tube was vortexed for 30 seconds and centrifuged for 10 minutes at 3000g. A 150 µL volume of supernatant was transferred to another tube that contained 200 µL of phosphate buffer; 25 µL of the mixture was injected into the HPLC system. The calibration curve was linear over the range 0.05 to 6 mg.L⁻¹. The method was highly reproducible. The coefficient of variation was 6.1% for a fluindione concentration of 0.1 mg.L⁻¹, 2.8% for a concentration of 0.5 mg.L⁻¹, and 2.3% for a concentration of 4 mg.L⁻¹ (10 measurements for each concentration). The estimated limit of quantification was 0.1 mg.L⁻¹ under the conditions described above, with a signal-to-noise ratio of 3 and a coefficient of variation lower than 20%.

Determination of genetic polymorphisms. DNA was extracted from the blood samples of patients consenting to the genetic ancillary study. For patients from the Bichat university hospital, the sample was directly sent to the Centre de Ressources Biologiques (CRB, DNA bank) of the hospital, and the DNA was extracted. For patients from the other two hospitals, samples were frozen at -20°C and sent every 3 months to the CRB for extraction and storage.

CYP2C9*2 and CYP2C9*3 (rs number 1799853 and 1057910, respectively) as well as VKORC1 genetic polymorphism for the 1173 C>T (rs number 9934438) were determined using custom Taq Man allelic discrimination assays (Applied Biosystems, Foster City, CA, USA) as in [40, 28]. They were performed all together at the end of study. The post-PCR-generated fluorescence intensity was quantified using an ABI 7000 Sequence detector System software version 1.2.3 (Applied Biosystems, Courtaboeuf, France). Each SNP genotyping procedure was performed in duplicate (separate experiments) for each patient. In cases of discordant results, samples were analyzed by DNA sequencing to confirm the genotype. Sequenced wild-type, homozygous and heterozygous patient samples were used as controls. All PCR reagents were purchased from Applied Biosystems.

We chose the VKORC1 1173 C>T SNP (rs9934438) to identify the major VKORC1 haplotype groups A and B. The C allele of the 1173 C>T SNP corresponds to the group B VKORC1 haplotype and the T allele to the group A VKORC1 haplotype. This SNP is in complete linkage disequilibrium with at least four other SNPs, which all individually allow the identification of VKORC1 haplotype groups [49, 50], which has been previously confirmed in a White French population [40].

Assessing model sensitivity

The PREPA study was an observational study, and to minimise the burden on patients, samples were taken only at the usual time for therapeutic monitoring. Figure S1 shows the dose-normalised fluindione concentrations versus time after the dose. Several patients skipped one or several doses, usually because the clinician was concerned about a quick rise in the INR, therefore for these patients the time after dose exceeds 24 hours, but most samples were taken 10 to 16 hours after the dose. The main plot displays the whole dataset, while the inset shows a zoom for time after dose lower than 48 hours, in order to better show the variability. Note that concentrations were normalised to the last dose taken before the measurement, so that for patients with changing doses the apparent variability may be larger since it does not take into account the whole dosing history. This figure shows that most of the samples were clustered between 10 and 15 hours.

Because there was concern regarding the ability of this design to properly estimate the parameters of the model, and also in light of the discrepancy with the results previously found in the ADAP study, we performed a small study to assess the robustness of the parameter

estimates. Due to time constraints this study was performed only for the PK model. We simulated 20 datasets with the population parameters estimated in the ADAP study and 20 datasets with the parameters estimated with the base model (without covariates) in the PREPA study. We then estimated the parameters of the PK model starting with initial estimates close to those of the ADAP study. The results are displayed in Supplementary Table S3, and show that despite the sparse design, the parameter estimates in both cases are close to the simulated values. There was more variability in the estimates from the datasets simulated with the parameters from the ADAP study (25% variability between runs versus 5%), partly because the IIV was larger in ADAP than in PREPA, but it was possible to clearly distinguish between the two sets of parameters.

Supplementary tables

Table S1: Drug classification used for the covariate analysis of the comedications in the PREPA study (from reference [42]).

Drugs increasing the thrombotic risk

A1 enzymatic inducers (decreasing INR)

A2 other drugs inhibiting coagulation

Drugs increasing the haemorrhagic risk

B11 anti-vitamin K agents

B12 aspirin, non-steroidal anti-inflammatory drugs

B13 heparins

B14 other drugs

B21 enzymatic inhibitors

B22 antibiotics with a negative effect on the intestinal flora

B23 drugs acting through another mechanism

Table S2: Range of parameter estimates for the covariate effects, obtained by multiple imputation (K=5 imputed datasets), compared to the estimate in the dataset where missing weight is imputed to the mean value.

Parameter	Estimate	Range MI
$\beta_{V,\text{men}}$	0.24 (41)	[0.17 – 0.25]
$\beta_{V,\text{weight}}$	0.57 (35)	[0.51 – 0.63]
$\beta_{\text{CL,age}}$	-3.26 (30)	[-3.38 – -2.96]
$\beta_{\text{CL,cordarone}}$	-0.18 (49)	[-0.19 – -0.17]
$\beta_{C_{50},\text{surgery}}$	-0.54 (25)	[-0.75 – -0.52]
$\beta_{\gamma,\text{surgery}}$	-0.46 (34)	[-0.68 – -0.50]
$\beta_{\gamma,\text{deroxat}}$	0.88 (31)	[0.81 – 2.03]

Table S3: Results from the simulation study: PK parameter estimates obtained on N=20 datasets simulated with the design of the original study, under two different set of parameters, ADAP=parameters estimated in the ADAP study [25]; PREPA=parameters estimated in the current study, with the base model (no covariates). We show the median and range of the parameters estimated in the 20 datasets for each simulation.

Parameter	ADAP			PREPA		
	Simulated	Estimated		Simulated	Estimated	
		Median	[range]		Median	[range]
V (L)	37.1	38.8	[23.0–65.3]	9.06	9.38	[8.73–10.20]
CL (L.hr ⁻¹)	0.49	0.42	[0.26–0.74]	0.12	0.12	[0.10–0.14]

Supplementary figure

Figure S1: Dose-normalised fluindione concentrations versus time after dose. Main plot: whole dataset; Inset: zoom for time after dose lower than 48 hours. When dose changes occurred, the last non-null dose before the measurement was taken for normalising.

